Indian Ustekinumab Exporters: Complete Supplier Ranking with Market Share — 23 Manufacturers (2026) — TransData Nexus

Q: Who is the largest ustekinumab supplier from India?

NIVIRA EXPORTS is the largest ustekinumab exporter from India with a 23.6% market share and export value of $299.9K.

Q: How many ustekinumab suppliers are there in India?

There are 23 active ustekinumab exporters in India, collectively shipping $1.3M worth of ustekinumab across 276 shipments according to Indian Customs (DGFT) records.

Q: What is the market share of top ustekinumab suppliers from India?

The top 5 ustekinumab suppliers from India — NIVIRA EXPORTS, GNH INDIA PHARMACEUTICALS LIMITED, BIOCON BIOLOGICS INDIA LIMITED, VAMA LIFECARE PRIVATE LIMITED, R B INTERNATIONAL — together control 70.8% of total ustekinumab export value from India.

Suresh Sormare

Ustekinumab

India Pharmaceutical Trade Intelligence

$1.3M23 Suppliers10 CountriesHS 30021500

ExportsIndia → BRAZIL71.5%India → JAPAN12.6%

ImportsNETHERLANDS → India$1.5M UNITED STATES → India$1.1M

#1 Supplier: NIVIRA EXPORTS #1 Buyer: AS PER

Ustekinumab Suppliers from India (2026) — 23 Exporters, $1.3M Market | TransData Nexus | TransData Nexus

Who Exports Ustekinumab from India — 23 Suppliers Behind a $1.3M Market

India's ustekinumab export market is supplied by 23 active exporters who collectively shipped $1.3M across 276 shipments. NIVIRA EXPORTS leads with a 23.6% market share, followed by GNH INDIA PHARMACEUTICALS LIMITED and BIOCON BIOLOGICS INDIA LIMITED. The top 5 suppliers together control 70.8% of total export value, reflecting a concentrated market structure.

Source: Indian Customs (DGFT)·Published March 2026

India's Top Ustekinumab Suppliers & Exporters — 23 manufacturers, $1.3M export market, top destinations and formulations — Ustekinumab supplier data — 23 exporters · $1.3M market · 276 shipmentsTransData Nexus · Indian Customs Data

Top Ustekinumab Exporters from India — Ranked by Export Value

NIVIRA EXPORTS is the leading ustekinumab exporter from India, holding a 23.6% share of the $1.3M market across 276 shipments from 23 exporters. The top 5 suppliers — NIVIRA EXPORTS, GNH INDIA PHARMACEUTICALS LIMITED, BIOCON BIOLOGICS INDIA LIMITED, VAMA LIFECARE PRIVATE LIMITED, R B INTERNATIONAL — collectively control 70.8% of total export value, indicating a highly concentrated market. Individual shares are: NIVIRA EXPORTS (23.6%), GNH INDIA PHARMACEUTICALS LIMITED (18.9%), BIOCON BIOLOGICS INDIA LIMITED (12.6%), VAMA LIFECARE PRIVATE LIMITED (9.9%), R B INTERNATIONAL (5.9%).

Top Ustekinumab Exporters from India

Ranked by export value · 23 active suppliers · Indian Customs (DGFT) data

Mar 2026

Top Ustekinumab Exporters from India — Ranked by Export Value. 23 active suppliers with export value, shipments, countries and formulations data compiled from Indian Customs records by TransData Nexus.
#	Supplier & Formulations	Value	Ships.	Ctry.	Share
1

Supplier Certification & Compliance Matrix

FDA, WHO-GMP, and EU GMP status for top Ustekinumab exporters

Certification and compliance status for top Ustekinumab suppliers from India
Supplier	US FDA	WHO-GMP	EU GMP	ANDAs	Notes
BIOCON BIOLOGICS INDIA LIMITED	Not Listed	Yes, as of June 2023	Yes	Not verified	WHO-GMP certified in June 2023; EU GMP compliant.
SERUM INSTITUTE OF INDIA PRIVATE LIMITED	Not Listed	Yes, as of April 202	Yes	Not verified	WHO-GMP certified in April 2022; EU GMP compliant.
PIRAMAL PHARMA LIMITED	Not Listed	Yes, as of February	Yes	Not verified	WHO-GMP certified in February 2025; EU GMP compliant.

TransData Nexus reviewed the regulatory standing of 3 leading Ustekinumab exporters from India. 0 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.

Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.

TransData Nexus Research · Mar 2026

Manufacturing Hub Analysis — Vendor Proximity

India's pharmaceutical clusters relevant to Ustekinumab sourcing

1Hyderabad — Bulk Drug Capital

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. Hyderabad's Genome Valley, India's first biotech cluster, provides advanced R&D infrastructure and a skilled talent pool, fostering innovation in biologics and biosimilars.

2Ahmedabad-Vadodara — Formulations Hub

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to major companies like Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's robust infrastructure, including well-connected ports and a supportive regulatory environment, makes it a strategic location for the manufacturing and export of finished pharmaceutical products.

3Mumbai-Thane-Raigad — Export Gateway

The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for the pharmaceutical industry. With 929 pharmaceutical units, Maharashtra is a significant contributor to India's pharma sector. The region's proximity to major ports facilitates efficient international distribution, making it a preferred location for companies focusing on export-oriented manufacturing.

Recent M&A, Collaborations & Capacity Expansions

Industry developments among top Ustekinumab exporters from India

August 2025

M&A

Biocon Biologics India Limited — Biocon Biologics acquires Viatris's biosimilars business for $3.34 billion

Biocon Biologics completed the acquisition of Viatris's global biosimilars business, gaining immediate access to commercial infrastructure, regulatory approvals, and a portfolio of over 20 biosimilar assets, including those in oncology, diabetes, and autoimmune therapies. - IMPACT: This acquisition is expected to enhance Biocon Biologics' capabilities in biosimilar production, potentially increasing its Ustekinumab export capacity.

Impact: This acquisition is expected to enhance Biocon Biologics' capabilities in biosimilar production, potentially increasing its Ustekinumab export capacity.

TransData Nexus Industry Research · Regulatory filings and press releases · Mar 2026

Common Questions — Ustekinumab Suppliers from India

Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus

Q Which ustekinumab supplier from India is the most reliable for bulk orders?

Based on shipment frequency and export consistency, NIVIRA EXPORTS leads with 61 recorded shipments worth $299.9K. GNH INDIA PHARMACEUTICALS LIMITED (33 shipments) and BIOCON BIOLOGICS INDIA LIMITED (5 shipments) are also established high-volume exporters.

Q How many ustekinumab manufacturers are there in India?

India has 23 active ustekinumab exporters with a combined export market of $1.3M across 276 shipments to 10 countries. The top 5 suppliers hold 70.8% of total export value.

Q What certifications should I verify?

Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).

Q What is the typical price range for ustekinumab from India?

Average FOB unit price: $1300.56 per unit, ranging from $0.05 to $4650.58. Average shipment value: $4.6K.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Ustekinumab

Ustekinumab

Who Exports Ustekinumab from India — 23 Suppliers Behind a $1.3M Market

Top Ustekinumab Exporters from India — Ranked by Export Value

Top Ustekinumab Exporters from India

Related Analysis

Need Details?

Supplier Certification & Compliance Matrix

Manufacturing Hub Analysis — Vendor Proximity

1Hyderabad — Bulk Drug Capital

2Ahmedabad-Vadodara — Formulations Hub

3Mumbai-Thane-Raigad — Export Gateway

Recent M&A, Collaborations & Capacity Expansions

Biocon Biologics India Limited — Biocon Biologics acquires Viatris's biosimilars business for $3.34 billion

Common Questions — Ustekinumab Suppliers from India

Q Which ustekinumab supplier from India is the most reliable for bulk orders?

Q How many ustekinumab manufacturers are there in India?

Q What certifications should I verify?

Q What is the typical price range for ustekinumab from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

4Baddi-Nalagarh — Tax Incentive Zone

5Sourcing Recommendations

Analysis Methodology